Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

102 results about "Cholanic acid" patented technology

Chenodeoxycholic acid (also known as chenodesoxycholic acid, chenocholic acid and 3α,7α-dihydroxy-5β-cholan-24-oic acid) is a bile acid. It occurs as a white crystalline substance insoluble in water but soluble in alcohol and acetic acid, with melting point at 165–167 °C.

Kit and detection method for simultaneously detecting 15 bile acid spectrums and 3 bile acid precursors in serum

PendingCN119000956Aeasy to handleFew operation steps and convenient and simpleComponent separationPortal veinBiliary tract
The invention discloses a kit for simultaneously detecting 15 bile acid spectrums and 3 bile acid precursors in serum and a detection method thereof. The 15 bile acid spectrums comprise cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid, glycocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, glycoursodeoxycholic acid, glycolithocholic acid, taurine cholic acid, taurine deoxycholic acid, taurine chenodeoxycholic acid, taurine ursodeoxycholic acid and bovine yellow lithocholic acid; the three kinds of bile acid precursors comprise 3alpha, 7alpha-dihydroxy cobalt prostate acid, 3alpha, 7alpha, 12alpha-trihydroxy cholestanic acid and 7alpha-hydroxy-4-cholesteryl-3-ketone. The invention further discloses a preparation method of the bile acid composition containing the 3 alpha, 7alpha-dihydroxy cobalt prostate acid and the 7alpha, 7alpha, 12alpha-trihydroxy cholestanic acid. The kit and the detection method can accurately detect the 15 bile acid spectrums and the 3 bile acid precursors at the same time, the detection time is short, the detection accuracy is high, and the clinical requirement for evaluating the enterohepatic cycle composed of the biliary tract system, the intestinal tract, portal vein circulation and hepatocytes is met to a certain extent.
Owner:SHANGHAI GEMPLE BIOTECH CO LTD

Application of oxime cholic acid analogue as TGR5 allosteric agonist

The invention belongs to the field of medicinal chemistry, and particularly discloses application of oxime cholic acid analogues as TGR5 allosteric agonists. The preparation method comprises the following steps: by taking cholic acid as a raw material, obtaining cholic acid intermediates of which the 12th site or the 7th site and the 12th site are oximes through a series of reactions, and then carrying out a series of modification on the 24th site and oximes of the intermediates to obtain the cholic acid analogue as shown in a formula 1 or a formula 2. According to the invention, a GloSensor cAMP accumulation experiment is adopted to test the functional activity and allosteric regulation mechanism of all compounds on TGR5 on a G protein dependent signal channel. Pharmacological results show that all the synthesized target compounds have relatively good agonist activity on TGR5, and can positively allosteric regulate the functional activity of chenodeoxycholic acid CDCA, that is, the target compounds disclosed by the invention are all TGR5 positive allosteric modulators or allosteric agonists. # imgabs0 # imgabs1 #
Owner:CHANGZHOU UNIV

Stereoselective crystallizations of cholic acids

PCT designated stage expiredWO2025096939A1SteroidsDrug compositionsCholic acidCholeic Acid
Methods for stereo-selectively crystallizing 3-keto-5β-cholanic acid ("3-KCA") and 3-keto ursodeoxycholic acid ("3-KUDCA") of exceptional purity, salts useful in carrying out such methods, particularly the t-butylamine and cyclohexylamine salts of 3-KCA, the t-butylamine salt of 3-KUDCA, and crystalline forms of such salts, and methods of making commercial steroids from such purified materials.
Owner:SANDHILL ONE LLC

Application of chenodeoxycholic acid in preparation of medicine for treating acne

The invention relates to application of chenodeoxycholic acid or pharmaceutically acceptable salt thereof in preparation of a medicine for treating acne. The chenodeoxycholic acid disclosed by the invention can be a natural organic compound or a synthetic organic compound, has relatively strong propionibacterium acnes inhibitory activity and a pharmacodynamic effect of resisting lipid secretion, and is used as an active component to be prepared into a pharmaceutical composition for treating acnes together with a pharmaceutically acceptable carrier.
Owner:EXPERIMENTAL RES CENT CHINA ACAD OF CHINESE MEDICAL SCI

Method and device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.
Owner:NANJING NORMAL UNIVERSITY

Application of 5beta-cholanic acid in enhancement of NK cell function and preparation of antiviral drugs

PendingCN120827569AOrganic active ingredientsDigestive systemAntigenPersistently infected
The invention discloses application of 5 beta-cholanic acid (5 beta-CA) in enhancement of NK cell functions and preparation of antiviral drugs. The NK cell function of a chronic hepatitis B (CHB) patient is depleted, it is found that the intracellular 5beta-CA level is reduced by screening differential metabolites of peripheral blood NK cells of the CHB patient, and the NK cell function of the CHB patient can be enhanced by exogenous supplementation of 5beta-CA; the function of NK cells of HBV persistently infected mice can be enhanced, and the level of virology indexes such as serum HBV related antigens and the like can be reduced. Specifically, the 5beta-CA enhances the NK cell function by activating a TGR5-cAMP-mTOR signal channel so as to play an anti-HBV role. The research finds that the improvement of the 5beta-CA level is expected to become a new thought for enhancing the NK cell function of a CHB patient, and a new technical means is provided for the treatment of CHB.
Owner:THE FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIV

Periodontitis related marker and application thereof

The invention belongs to the technical field of biomedicine, and particularly provides a periodontitis related marker which comprises glycochenodeoxycholic acid. The concentration change of the periodontitis related marker provided by the invention is directly related to the pathological mechanism of periodontitis. As bound bile acid, the bile acid is slowly degraded in saliva. And the glycochenodeoxycholic acid in the saliva is synthesized from gingival fibroblasts, so that the influence of systemic inflammatory diseases is greatly eliminated. Glycine chenodeoxycholic acid in saliva is used as a specific biomarker, a non-invasive, high-sensitivity and high-specificity detection method, system and equipment are established, objective quantitative evaluation and dynamic monitoring of periodontitis activity are achieved, the hysteresis limitation of traditional diagnosis is broken through, a convenient and non-invasive accurate diagnosis tool is provided for clinic, and the clinical application prospect is wide. And the technical blank of periodontitis activity noninvasive diagnosis is filled.
Owner:HOSPITAL OF STOMATOLOGY SUN YAT SEN UNIV

Cellular uptake

To provide cellular uptake.SOLUTION: The invention provides a bile acid or a pharmaceutically acceptable salt thereof for use in a method for treating the human or animal body, the method comprises administering to the human or animal body a therapeutic compound, where: a. the bile acid is chenodeoxycholic acid or deoxycholic acid; b. optionally, the bile acid is employed in conjunction with EDTA; c. in the method, the bile acid or salt thereof and EDTA are used to enable or enhance intracellular uptake of the therapeutic compound.SELECTED DRAWING: None
Owner:アクセス(ユーケー)リミテッド

Composition for improving tear stains of dogs and cats containing bile acid and bifidobacterium animalis subsp. Lactis

The invention provides a composition containing bile acid and bifidobacterium animalis subsp. Lactis for improving tear stains of dogs and cats. The composition is prepared from the bile acid and the bifidobacterium animalis subsp. Lactis ZYhyy-017, and the composition is prepared from the bile acid, the bifidobacterium animalis subsp. Lactis ZYhyy-017, the bifidobacterium animalis subsp. Lactis ZYhyy-017 and the bifidobacterium animalis subsp. Lactis ZYhyy-017. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.37292, and the preservation date is January 6, 2026. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The bile acid is chenodeoxycholic acid (CDCA). The composition regulates and controls a bile acid-porphyrin metabolic pathway in a targeted manner through the synergistic effect of bile acid and bifidobacterium animalis subsp. Lactis ZYhyy-017, porphyrin metabolism in pets is regulated from the source, intestinal and liver axis metabolism and liver functions are optimized, long-acting and safe improvement of tear stains of dogs and cats is achieved, and the composition has a wide application prospect. Meanwhile, the technical blank that bile acid and specific probiotics are synergistically applied to the field of tear stain improvement of dogs and cats is filled up, and the actual requirement for tear stain root improvement in pet feeding is met.
Owner:北京和益源生物技术有限公司

Synthesis method of N-goose deoxycholyl-L-aspartic acid and application of N-goose deoxycholyl-L-aspartic acid in preparation of medicines for improving metabolism-related fatty liver diseases

The invention discloses a synthesis method of N-goose deoxycholyl-L-aspartic acid and application of the N-goose deoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolism-related fatty liver diseases. According to the method provided by the invention, chenodeoxycholic acid and L-dimethyl aspartate hydrochloride are taken as raw materials, and a chenodeoxycholic acid-dimethyl aspartate intermediate is synthesized, so that a target compound-N-chenodeoxycholyl-L-aspartic acid with a brand new structure is efficiently prepared. The compound shows a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as fatty degeneration, inflammation and fibrosis of the liver. The invention provides a brand new solution for major clinical challenges of insufficient curative effect, large side effect, drug withdrawal rebound and the like of the current MAFLD treatment drug, and provides a candidate compound with a wide prospect for developing a novel efficient MAFLD treatment drug.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

7beta-hsdh enzyme mutant, encoding gene and application thereof

This invention provides a 7β-HSDH enzyme mutant, its encoding gene, and its applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.
Owner:QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES)

Impurity removal method of chenodeoxycholic acid crude product

The invention provides an impurity removal method of a chenodeoxycholic acid crude product, which comprises the following steps: dissolving the chenodeoxycholic acid crude product and glucose in a solvent, adding alkali to control the pH value of the system to be 8-10, and adding thiourea to react so as to convert 22-ene-chenodeoxycholic acid impurities into chenodeoxycholic acid. According to the impurity removal method provided by the invention, the 22-ene-chenodeoxycholic acid impurity in chenodeoxycholic acid can be effectively removed without adopting a heavy metal catalyst and the like, and the method is convenient to operate, mild in condition, low in production risk and suitable for large-scale industrial production.
Owner:ZHE JIANG HUA NA YAO YE YOU XIAN GONG SI

Use of hhex agonists in promoting anti-tumor immunity

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.
Owner:UNIV OF SCI & TECH OF CHINA

Hyaluronic Acid Nanoparticles Comprising NADPH Oxidases Inhibitors and Uses in Treating Cancer

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.
Owner:EMORY UNIVERSITY

Variants of 7 alpha-hydroxysteroid dehydrogenase and related application

The invention belongs to the field of biology, discloses a variant of 7 alpha-hydroxysteroid dehydrogenase, and aims to improve the catalytic efficiency and stability of catalyzing chenodeoxycholic acid (CDCA) to be converted into UDCA precursor 7-ketolithocholic acid, and particularly, the variant is obtained by carrying out single mutation or multipoint combined mutation on the 93th site, the 94th site, the 96th site, the 146th site, the 150th site, the 155th site, the 188th site, the 189th site, the 190th site, the 195 site, the 195th site, the 196th site, the 196th site, the 195th site, the 195th site, the 195th site, the 196th site, the 199th site, the 200th site, the 204th site and the 249th site
Owner:SHANGHAI ZHUYAO TECH CO LTD

Application of chenodeoxycholic acid in preparation of medicine for treating allergic diseases

The invention belongs to the technical field of biological medicines, and particularly relates to application of chenodeoxycholic acid in preparation of drugs for treating allergic diseases. It is found that CDCA can effectively inhibit pyroptosis and secretion of proinflammatory factors, expression of complement inhibition proteins CD46, CD55 and CD59 is remarkably up-regulated, expression of the complement inhibition proteins CD46, CD55 and CD59 is finally promoted, and occurrence and development of allergic diseases are effectively relieved. In a mouse model, CDCA can significantly improve OVA-induced food allergy symptoms, and has application prospects in treatment of allergic diseases.
Owner:WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY

Method for detecting impurities of 22-ene-ursodesoxycholic acid and 22-ene-chenodesoxycholic acid in ursodesoxycholic acid

The invention relates to the technical field of pharmaceutical analysis, in particular to a method for detecting impurities of 22-ene-ursodesoxycholic acid and 22-ene-chenodesoxycholic acid in ursodesoxycholic acid. According to the method, a high performance liquid chromatograph is used, a sodium dihydrogen phosphate dihydrate aqueous solution-acetonitrile is used as a mobile phase, isocratic elution is adopted, an octyl silane bonded silica gel column is used as a chromatographic column for separation, and an ultraviolet detector is used for detection. The detection method can effectively separate and identify 22-ene-ursodesoxycholic acid and 22-ene-chenodesoxycholic acid impurities in ursodesoxycholic acid, methodology verifies that all inspection indexes meet regulations, the detection result is accurate and reliable, and the method has the advantages of being simple, convenient, exclusive, accurate and high in sensitivity. And a guarantee is provided for monitoring the quality stability and clinical medication safety of the ursodesoxycholic acid.
Owner:HUNAN JIUDIAN HONGYANG PHARM CO LTD

Feed additive for improving ovary color of scylla paramamosain and application thereof

The invention relates to the technical field of aquaculture feed, in particular to a feed additive for improving ovary color of scylla paramamosain and application of the feed additive. The feed additive is prepared from the following raw material components in parts by mass: 30-60 parts of Chinese wolfberry fruit powder, 10-30 parts of a marigold extract, 2-8 parts of chenodeoxycholic acid and 5-15 parts of vitamin E powder. The additive systematically solves the technical bottlenecks of low absorptivity and unstable deposition of natural pigments in crab bodies through the synergistic effect of all the components. When the feed additive is added into feed for fattening female scylla paramamosain, the ovary redness value can be remarkably increased, the color is rich and natural, and meanwhile, the growth of parent crabs and the development of gonad are promoted. The feed is completely prepared from natural raw materials, is safe, free of residues and controllable in cost, and provides an effective scheme for realizing high-valued and green cultivation of scylla paramamosain'red cream crab '.
Owner:EAST CHINA SEA FISHERIES RES INST CHINESE ACAD OF FISHERY SCI +1

Method for extracting biological medicine chenodeoxycholic acid through gel adsorption

The invention relates to the technical field of extraction and manufacturing of biological drugs, in particular to a method for extracting a biological drug chenodeoxycholic acid through gel adsorption. According to the method, chicken bile is used as a raw material, sodium hydroxide saponification, hydrochloric acid acidification, organic reagent impurity removal, calcium chloride precipitation and ethyl acetate extraction are adopted to obtain free bile acid, chenodeoxycholic acid is separated and purified through polymer gel containing beta-cyclodextrin, and high-purity chenodeoxycholic acid is obtained. According to the method disclosed by the invention, beta-cyclodextrin is used as a cross-linking agent and is subjected to free radical polymerization with a polymer monomer to form beta-cyclodextrin-containing polymer gel, and the beta-cyclodextrin-containing polymer gel and chenodeoxycholic acid can form a stable inclusion compound in part of an organic solvent and an aqueous solution, so that the beta-cyclodextrin-containing polymer gel has a good adsorption effect; and the method has the advantages of high safety, high selectivity, recyclability and the like, and has a wide industrial application prospect.
Owner:BEIJING NORMAL UNIV AT ZHUHAI

Novel 7beta-hydroxysteroid dehydrogenase gene and application thereof

The invention discloses a novel 7 beta-hydroxysteroid dehydrogenase gene and application thereof, and belongs to the technical field of enzyme engineering and biological catalysis. According to the invention, a 7beta-hydroxysteroid dehydrogenase gene with high conversion rate is excavated from a database, the 7beta-hydroxysteroid dehydrogenase gene and a 7alpha-hydroxysteroid dehydrogenase gene are subjected to heterologous expression in different chassis cells, and recombinant bacteria for efficiently preparing ursodesoxycholic acid are constructed. The constructed recombinant strain is used for producing ursodesoxycholic acid through whole-cell catalysis of chenodeoxycholic acid, the feeding amount is 6 g / L, the catalytic reaction time is 24 h, and the conversion rates of recombinant escherichia coli and pichia pastoris are 87.6% and 97.8% respectively.
Owner:TIANJIN UNIV OF SCI & TECH

Bile acid composition for fish and shrimp feed and preparation method thereof

The invention belongs to the technical field of fish and shrimp breeding feed additives, and particularly relates to a bile acid composition for fish and shrimp feed and a preparation method of the bile acid composition, and the composition comprises the following components in parts by weight: 50-60 parts of hyocholic acid, 40-55 parts of chenodeoxycholic acid, 40-60 parts of hyodeoxycholic acid, 30-45 parts of methionine glycine dipeptide and 60-115 parts of a compound plant extract. According to the invention, the methionine glycine dipeptide is used for improving the lipid metabolism capability of fishes and shrimps; the composite plant extract is used for enhancing the immunity and the anti-stress capability of the fish and the shrimps.
Owner:山东凯龙生物科技有限公司

Synthesis method of n-chenodeoxycholyl-l-aspartic acid and application thereof in preparation of medicine for improving metabolic related fatty liver disease

The application discloses a synthesis method of N-chenodeoxycholyl-L-aspartic acid and application of the N-chenodeoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolic associated fatty liver disease. The method provided by the application uses chenodeoxycholic acid and L-aspartic acid dimethyl ester hydrochloride as raw materials, synthesizes a chenodeoxycholic acid-aspartic acid dimethyl ester intermediate, and efficiently prepares a target compound, N-chenodeoxycholyl-L-aspartic acid, which is a novel structure, the compound exhibits a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as liver steatosis, inflammation and fibrosis. The application provides a novel solution for major clinical challenges such as insufficient treatment effect, large side effect and rebound after drug withdrawal of current MAFLD treatment medicines, and provides a candidate compound with broad prospects for developing a new high-efficiency MAFLD treatment medicine.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

A composition for clearing heat and detoxifying, protecting liver and improving eyesight, and a medicine preparation and application thereof

This invention relates to the field of traditional Chinese medicine technology, specifically to a composition for clearing heat and detoxifying, protecting the liver and improving eyesight, its pharmaceutical preparation and application. The raw materials of the composition, by weight, include the following components: 10-30 parts ursodeoxycholic acid, 1-5 parts chenodeoxycholic acid, 5-15 parts Lycium barbarum polysaccharide, 5-18 parts betaine, 1-5 parts glycyrrhizic acid, 0.2-5 parts glycyrrhetinic acid, and 1-5 parts glycyrrhizin. This invention combines these components to achieve the effects of clearing heat and detoxifying, protecting the liver and improving eyesight. Pharmacological experiments have demonstrated that it has significant antipyretic effects, prevents and treats eye fatigue, and improves acute liver injury.
Owner:JILIN HUAKANG PHARM CO LTD

A method for synthesizing 7-ketolithocholic acid from BA

The application discloses a chemical synthesis method of 7-ketolithocholic acid (3alpha-hydroxy-7-keto-5beta-cholestane-24-oic acid), and belongs to the field of organic chemical synthesis. The 7-ketolithocholic acid is synthesized from a plant source compound BA through steps of glycol or neopentyl glycol protection, oxidation, Wittig reaction, deprotection, reduction and hydrolysis. The raw material used for synthesizing the 7-ketolithocholic acid is cheap and easy to obtain, the synthesis steps are simple and convenient to operate, the yield is high, the environment is friendly, and the industrialized production is facilitated.
Owner:JIANGSU JIAERKE PHARMA GRP CORP +1

Application of chenodeoxycholic acid in preparation of medicine for preventing and / or treating acute pancreatitis

The invention discloses application of chenodeoxycholic acid in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of biological medicines. The invention discloses the new pharmaceutical application of chenodeoxycholic acid on acute pancreatitis or severe acute pancreatitis for the first time. By simulating two clinically related acute pancreatitis models, namely, a raulein-induced mouse acute pancreatitis model and a pancreatic duct retrograde injection sodium taurocholate-induced mouse severe acute pancreatitis model, through experimental verification, the chenodeoxycholic acid CDCA is subjected to intragastric administration or intraperitoneal injection to obtain the acute pancreatitis model. The occurrence and development of acute pancreatitis or severe acute pancreatitis related to the two models can be obviously improved, so that chenodeoxycholic acid can be expected to be applied to clinical prevention / treatment of AP.
Owner:YANGZHOU FIRST PEOPLES HOSPITAL +1

Method for detecting related substances in synthesis of 24-norursodeoxycholic acid

The invention belongs to the technical field of drug detection and analysis, and particularly relates to a method for detecting related substances in 24-norursodeoxycholic acid synthesis. According to the method for detecting related substances in 24-norursodeoxycholic acid synthesis, a chromatographic column with octadecylsilane chemically bonded silica as a filler is selected, a phosphate solution-acetonitrile is used as a mobile phase, and a differential refraction detector is used as a detector. The detection method has a relatively good retention effect on the 3 [alpha]-hydroxy-7-keto-5beta-cholestane-23-acid and related 23 carbon impurities, and the sample peak shape is good. Meanwhile, the detection method also has the advantages of strong specificity, good repeatability, wide linear range and high sensitivity, and can conveniently and effectively realize the detection and analysis of the 3alpha-hydroxy-7-keto-5beta-cholestane-23-acid intermediate and related 23 carbon impurities.
Owner:ZHONGSHAN BAILING BIOTECHNOLOGY CO LTD

Evaluation method of bile acids in alleviating intestinal inflammation in spotted acorns

This invention discloses an evaluation method for bile acids in alleviating intestinal inflammation in grouper, belonging to the field of aquaculture technology. Addressing the intestinal inflammation problem caused by feed oxidation, pathogen infection, or water quality deterioration in intensive grouper farming, this invention proposes to achieve efficient regulation of intestinal health by adding a compound bile acid composition to the feed. The core technical solution of the method is as follows: a compound bile acid is formed by compounding porcine deoxycholic acid, chenodeoxycholic acid, and porcine cholic acid in a specific ratio, combined with a carrier premixing process to prepare a bile acid premix, which is then added to the basal feed at 0.15%-0.60% of the total feed mass. This invention effectively alleviates enteritis symptoms in grouper by enhancing the integrity of the intestinal epithelial structure, repairing damaged mucosal barriers, regulating inflammatory responses, and optimizing intestinal flora composition. It provides a safe and efficient technical solution for replacing feed antibiotics in aquaculture, with significant economic and ecological benefits.
Owner:HAINAN UNIV +1

Silanization purification method for ursodesoxycholic acid prepared by biological enzyme method

The invention discloses a silanization purification method for ursodesoxycholic acid prepared by a biological enzyme method, and belongs to the field of biological pharmacy. According to the method, the whole-cell reaction liquid is used as a purification object, insoluble macromolecular impurities are removed through preliminary impurity removal and high-concentration acetone-water dissolution, the target content of UDCA is 80% or above successfully, and the product is pure white; the method comprises the following steps: carrying out a reaction on a UDCA silanization derivative and-OH by using a silanization reagent, separating the UDCA silanization derivative from other silanization derivatives, and hydrolyzing the UDCA silanization derivative to realize purification of UDCA. The content of CDCA in the final product is effectively controlled to be 0.5% or below, the purity of the UDCA crude product is improved from 53% to 98.5% or above, and the requirements of UDCA bulk drugs are met. The method is simple in process and low in cost, the obtained product is high in purity, the chenodeoxycholic acid impurity content is low, and the chenodeoxycholic acid can be used as a raw material of a pharmaceutical preparation.
Owner:JIANGSU BANGZE BIOLOGICAL MEDICINE TECH CO LTD

7 beta-HSDH enzyme mutant derived from ruminococcus torsionosus and application of 7 beta-HSDH enzyme mutant

The invention discloses a ruminococcus torsionosus-sourced 7beta-HSDH enzyme mutant and application thereof, the ruminococcus torsionosus-sourced 7beta-HSDH enzyme is taken as a research object, a series of single-point mutation and combined mutation of the 7beta-HSDH enzyme are provided, and compared with wild type 7beta-HSDH enzyme, the thermal stability of the 7beta-HSDH enzyme mutant is improved by 1-20 DEG C, and the 7beta-HSDH enzyme mutant has the advantages that the 7beta-HSDH enzyme mutant has the advantages that the 7beta-HSDH enzyme mutant can be used for preparing the 7beta-HSDH enzyme mutant; compared with a wild type 7beta-HSDH enzyme, the 7 beta-HSDH enzyme has the advantages that the Tm value of the (C217I and E252K) mutant is improved by 1.2-4.2 times, the enzyme activity of the (C217I and E252K) mutant is 4.2 times that of the wild type 7beta-HSDH enzyme, and the (T103I, D251K, L229K and S161A) mutant has ultrahigh heat stability, the Tm value is close to 68 DEG C, and 50% of enzyme activity is maintained, so that the 7 beta-HSDH enzyme can be used for preparing the 7 beta-HSDH enzyme. Compared with a wild type 7 beta-HSDH enzyme, the 7 beta-HSDH enzyme mutant provided by the invention has wider application conditions, is more suitable for efficiently producing ursodesoxycholic acid from 3 alpha-hydroxy-7-oxo-5beta-cholanic acid (7-ketolithocholic acid, 7-KLCA) by a biological conversion method, and is beneficial to large-scale production and industrial application.
Owner:BIORTUS BIOSCI +1

Pharmaceutical composition of chenodeoxycholic acid for pediatric use

The present invention relates to the preparation of pharmaceutical compositions comprising chenodeoxycholic acid (CDCA) is used in the treatment of cerebrotendineous xanthomatosis (CTX), especially in the form of sachet and for pediatric use.
Owner:HUMANIS SAĞLIK A.Ş